M&A Deal Summary

Ampersand Capital Partners Acquires ALPCO

On September 21, 2020, growth capital firm Ampersand Capital Partners acquired distribution company ALPCO

Acquisition Highlights
  • This is Ampersand Capital Partners’ 1st transaction in the Distribution sector.
  • This is Ampersand Capital Partners’ 52nd transaction in the United States.
  • This is Ampersand Capital Partners’ 1st transaction in New Hampshire.

M&A Deal Summary

Date 2020-09-21
Target ALPCO
Sector Distribution
Buyer(s) Ampersand Capital Partners
Deal Type Recapitalization

Target

ALPCO

Salem, New Hampshire, United States
website
ALPCO is an importer and distributor of immunoassay-based products for the North American life science markets. ALPCO is a provider of proprietary and distributed diagnostics solutions, with over 60 collaborating partners from around the globe. ALPCO was founded in 1990 and is based in Salem, New Hampshire.

Search 191,421 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ampersand Capital Partners

Wellesley, Massachusetts, United States

Investor Investor Investor Investor Investor

website


Category Growth Capital Firm
Founded 1988
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


DEAL STATS #
Overall 57 of 79
Sector (Distribution) 1 of 1
Type (Recapitalization) 3 of 6
State (New Hampshire) 1 of 1
Country (United States) 52 of 65
Year (2020) 4 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-09-21 GeneWerk

Heidelberg, Germany

GeneWerk is a provider of cell and gene therapy sponsors with patient testing services in compliance with guidance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). GeneWerk was founded in 2014 and is based in Heidelberg, Germany.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-05 Genezen Laboratories

Indianapolis, Indiana, United States

Genezen Laboratories is a cell and gene therapy contract development and manufacturing organization (CDMO) focused on early-phase process development, vector production, and analytical testing services. Genezen Laboratories is based in Indianapolis, Indiana.

Buy -